Entries by Ayal Ronen

A Strategic Source of Funding from Basic Research to Clinical Trials

Non dilutive funding is available for every conceivable kind of research or development effort, whether it is an academic or industry project. Government agencies, as well as state organizations and private foundations, release daily hundreds of different solicitations covering topics that are of interest to public health and medical and life science research. Although these […]

Webinar: Non-Dilutive Funding for Industry-Academic Partnerships

Industry-Academic partnerships drive life science discoveries to market, and the importance of sustaining and nurturing these relationships is high on the agenda of both industry and academic leaders. Over the past several years we are witnessing a changing direction at the NIH and other government granting agencies aimed at supporting these relationships. We will give […]

Webinar: Funding Cancer R&D with Non-dilutive Capital; an Emphasis on NIH Sources

NIH alone awards roughly $5.5B annually to Cancer related R&D grants and contracts. The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage clinical research and validation. In the upcoming webinar in the series of summer educational webinars, FreeMind’s VP, Ayal Ronen, will discuss key cancer […]

Webinar: Medical Device Non-Dilutive Funding: Trends & Opportunities

In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies. The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage clinical research and validation. In this webinar […]

Webinar: BARDA Funding Opportunities for Life Science Organizations

The Biomedical Advanced Research and Development Authority (BARDA) develops and purchases the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies. Interestingly, between 2010 and 2012, BARDA experienced a budget increase of some 60% from $337.5M to roughly $547M. For Life Science organizations, this translates into hundreds of millions of dollars in potential […]

Webinar: MJFF joint presentation; Neurological Disorders with an emphasis on Parkinson’s

FreeMind is proud to host the Michael J. Fox Foundation on the upcoming summer educational webinar focusing on Parkinson’s and other Neurological disorders. Parkinson’s is a complex disease that varies greatly among affected individuals. For The Michael J. Fox Foundation, there is one clear measure of success: delivering patients better treatments and, ultimately, a cure for Parkinson’s disease. Today, MJFF is […]

Webinar: Details of a Detailed Budget

Assembling a budget for your grant is typically the last item to be addressed. Reason being that the figures you are suggesting must reflect the work you are proposing to complete. That said, simply stating the cost per item is hardly enough, and a properly constructed justification is mandatory and weighs heavily on approval of […]

Webinar: SBIR/STTR Program; An Industry Gateway to Additional Non-Dilutive Funding

FreeMind’s VP Ayal Ronen will discuss the SBIR/STTR program viewed by many as a critical source of funding for the Small Business Life Science community. Through the SBIR/STTR program some $700,000,000 are awarded annually by the NIH specifically to research project grants. Despite a continuous decline in success rates, this remains a crucial path small businesses must […]